BioClinica Inks Seven New Trident IWR Deals in First Quarter 2011

April 8, 2011

Company News Release

BioClinica

announced that Trident IWR  (interactive web response) has been

selected

by seven new clients in the first quarter of 2011 to help build and deploy complex trials efficiently without the need for programming.

Trident IWR provides clinical operations personnel a way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a less costly manner and in a fraction of the time than previous alternatives. Trident IWR does not require programming for each new clinical trial and it configures both web and voice at the same time..

In December of 2010, GlaxoSmithKline signed an

agreement

with BioClinica to standardize on the Trident IWR system, selecting the technology as a way to manage their global trials across Phase I-IV clinical trials.

“Since we launched Trident IWR in October 2010, BioClinica has received incredible industry-wide response,” said Mark Weinstein, CEO of BioClinica. “With seven companies making the decision to standardize their complex trials with Trident IWR in just the first quarter of 2011 alone, we are happy to confirm that our best-in-class solution is successfully providing the efficiencies, cost savings and overall support needed by today’s top pharmaceutical companies.”